Monograph

The Ministry of Health’s Drug Advisory Committee has not recommended:

• Romosozumab or teriparatide for inclusion on the MOH List of Subsidised Drugs for treating postmenopausal women with osteoporosis who are at high risk for fracture; and
• Teriparatide for inclusion on the MOH List of Subsidised Drugs for treating men with primary or hypogonadal osteoporosis who are at high risk for fracture, or patients with glucocorticoid-induced osteoporosis who are at high risk for fracture

due to uncertain extent of clinical benefit and unfavourable cost-effectiveness compared with subsidised alternatives.